Lauren Merendino

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Brisbane, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Charles N. York II, as Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Lauren Merendino

Form 4 holding Director

ESSA Pharma Inc.

Security class
Options
Shares / value
25,000
Estimated value
Report date
25 Mar 2024
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Chief Commercial Officer

Myovant Sciences Ltd.

Security class
Common Shares
Shares / value
0
Estimated value
Report date
10 Mar 2023
Price
$27.00
Ownership
Direct
Form 4 holding Chief Commercial Officer

Myovant Sciences Ltd.

Security class
Performance Stock Unit
Shares / value
0
Estimated value
Report date
10 Mar 2023
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Chief Commercial Officer

Myovant Sciences Ltd.

Security class
Stock Options (Right to Buy)
Shares / value
0
Estimated value
Report date
10 Mar 2023
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount

Insider Reports Filed by Lauren Merendino

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .